Greenspan SL et al. - In postmenopausal women with breast cancer with or without aromatase inhibitor (AI) therapy, once-weekly oral risedronate was beneficial for spine and hip bone mineral density (BMD), reduced bone turnover, and was well tolerated. Methods
Study to examine prevention of breast cancer–related bone loss
87 postmenopausal women after chemotherapy for BCa were randomly assigned to once-weekly risedronate 35 mg or placebo for 24 mos
Outcomes included BMD and turnover markers
Results
At study initiation, 13% of pts were on an AI
After 24 mos, there were differences of 1.6 to 2.5% at the spine and hip BMD between the placebo and risedronate groups
At study completion, 44% were on an AI
Adjusting for an AI, women on placebo plus AI had a decrease in BMD of 4.8% ± 0.8% at the spine and 2.8% ± 0.5% at the total hip
In women on risedronate + AI, the spine decreased by 2.4% ± 1.1% and was stable at the hip
Women in the placebo group not on an AI, maintained BMD at the spine, and had a 1.2% ± 0.5% loss at the total hip
Women who received risedronate but no AI had the greatest improvement in BMD of 2.2% ± 0.9% at the total hip
Bone turnover was reduced with risedronate
There were no differences in adverse events between the groups
See all
